<DOC>
	<DOC>NCT01909856</DOC>
	<brief_summary>This study is to assess the efficacy and safety of palonosetron in preventing the acute and delayed emesis induced by 3-day highly emetogenic chemotherapy. A double-blind, crossover design is used and granisetron is the positive control.</brief_summary>
	<brief_title>The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>Patients diagnosed with malignant tumors who can receive 3day chemotherapy regimens defined by the protocol; The twocycle sequential chemotherapy must be the same in drugs, dosage, sequence and routes of administration; Patients are prohibited from any other chemotherapy drugs during the study, as well as other antiemesis, sedative and psychotropic drugs within 5 days after chemotherapy; Life expectancy â‰¥ 3 months; Adequate hematologic function; Adequate hepatic function; Adequate renal function; At least 2 weeks away from the last chemotherapy; Patients signed written informed consent. Pregnant or lactating women; History of anticipatory vomiting; Radiation therapy on the abdomen or pelvis within one week prior to study entry; Concomitant use of other drugs which may affect the antiemetic effects (such as omeprazole, amifostine, etc.); Patients with gastrointestinal obstruction; Patients with severe heart disease, liver or renal disease, or metabolism disorders; Patients with epilepsy or using sedative or psychotropic drugs; Patients with diabetes or with contraindication for corticosteroids; Patients who received antiemetic drugs or experienced nausea or vomiting within 24 hours prior to study entry; Patients with brain metastasis or intracranial hypertension; Hypersensitivity to 5HT3 receptor antagonist; Patients with active infection; Other conditions that the investigator considered as unsuitable for chemotherapy; Subjects participating in other clinical trials.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>